$-0.11 EPS Expected for Xenon Pharmaceuticals Inc. (XENE)

February 24, 2018 - By Migdalia James

 $ 0.11 EPS Expected for Xenon Pharmaceuticals Inc. (XENE)

Analysts expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to report $-0.11 EPS on March, 14.They anticipate $0.21 EPS change or 65.63 % from last quarter’s $-0.32 EPS. After having $-0.43 EPS previously, Xenon Pharmaceuticals Inc.’s analysts see -74.42 % EPS growth. The stock decreased 1.20% or $0.04 during the last trading session, reaching $3.7. About 29,929 shares traded. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has declined 39.94% since February 24, 2017 and is downtrending. It has underperformed by 56.64% the S&P500.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Ratings Coverage

Among 5 analysts covering Xenon Pharmaceuticals (NASDAQ:XENE), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Xenon Pharmaceuticals had 14 analyst reports since August 11, 2015 according to SRatingsIntel. Jefferies maintained Xenon Pharmaceuticals Inc. (NASDAQ:XENE) rating on Monday, September 11. Jefferies has “Buy” rating and $5.0 target. On Friday, October 21 the stock rating was initiated by Stifel Nicolaus with “Buy”. The rating was maintained by Jefferies on Friday, August 4 with “Buy”. The stock of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has “Buy” rating given on Tuesday, August 11 by Canaccord Genuity. The stock of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has “Buy” rating given on Tuesday, June 27 by Canaccord Genuity. As per Monday, June 12, the company rating was maintained by Jefferies. The stock has “Buy” rating by Jefferies on Friday, October 30. Jefferies reinitiated it with “Buy” rating and $13 target in Monday, March 13 report. The stock of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has “Sell” rating given on Wednesday, September 2 by Zacks. The stock of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) earned “Sell” rating by Zacks on Wednesday, August 19.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company has market cap of $66.59 million. The firm uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It currently has negative earnings. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency.

More notable recent Xenon Pharmaceuticals Inc. (NASDAQ:XENE) news were published by: Globenewswire.com which released: “Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in …” on March 24, 2017, also Seekingalpha.com with their article: “Xenon Pharmaceuticals’ (XENE) CEO Simon Pimstone on Q2 2017 Results – Earnings …” published on August 06, 2017, Marketwatch.com published: “Xenon Pharmaceuticals Inc.” on October 21, 2016. More interesting news about Xenon Pharmaceuticals Inc. (NASDAQ:XENE) were released by: Globenewswire.com and their article: “Xenon Pharmaceuticals Outlines Key Milestones for 2018” published on January 08, 2018 as well as Globenewswire.com‘s news article titled: “Xenon Names Dr. James R. Empfield Senior Vice President, Drug Discovery” with publication date: February 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: